Status:
RECRUITING
Infrared Photobiomodulation in Humans With Epilepsy
Lead Sponsor:
Beth Israel Deaconess Medical Center
Conditions:
Drug Resistant Epilepsy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Drug-resistant epilepsy represents roughly 40% of people with epilepsy. It is very challenging to stop seizures in this condition, and the treatment options are limited. This study aims to investigate...
Detailed Description
Epilepsy affects 12 out of every 1000 people in the United States (1.2%). Of those, roughly 40% have drug-resistant epilepsy, meaning seizures do not stop despite good doses given with two different a...
Eligibility Criteria
Inclusion
- Drug resistant epilepsy
- Age 18 or older
- Average seizure rate of at least 2 seizures per month
- Accurate seizure diary with at least 3 months recorded
Exclusion
- Implanted intracranial neurostimulation device (DBS or RNS)
- Intracranial shunt
- Skin photosensitivity
- Cancer on scalp
- Taking any medication that can cause photosensitivity
Key Trial Info
Start Date :
November 25 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 25 2027
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT07145489
Start Date
November 25 2025
End Date
September 25 2027
Last Update
December 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
BIDMC
Boston, Massachusetts, United States, 02215